Zenas BioPharma, Inc. (NASDAQ:ZBIO) Receives Average Recommendation of “Hold” from Analysts

Zenas BioPharma, Inc. (NASDAQ:ZBIO) has received a consensus recommendation of “Hold” from the nine research firms that are currently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating on the company. The average 1-year target price among analysts that have covered the stock in the last year is $44.1429.

Several equities research analysts have recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Zenas BioPharma in a research report on Monday, December 29th. Guggenheim upped their target price on shares of Zenas BioPharma from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Monday, March 16th. Zacks Research downgraded shares of Zenas BioPharma from a “hold” rating to a “strong sell” rating in a report on Tuesday, March 17th. Jefferies Financial Group restated a “buy” rating and issued a $48.00 price target on shares of Zenas BioPharma in a research report on Tuesday, January 6th. Finally, Morgan Stanley boosted their price objective on shares of Zenas BioPharma from $19.00 to $21.00 and gave the stock an “equal weight” rating in a report on Tuesday, March 17th.

Zenas BioPharma Trading Up 5.4%

Zenas BioPharma stock opened at $22.19 on Thursday. Zenas BioPharma has a 52 week low of $6.11 and a 52 week high of $44.60. The company has a debt-to-equity ratio of 0.32, a quick ratio of 5.61 and a current ratio of 5.61. The firm has a market capitalization of $1.27 billion, a PE ratio of -2.84 and a beta of -1.94. The business’s 50-day simple moving average is $23.17 and its 200-day simple moving average is $27.30.

Zenas BioPharma (NASDAQ:ZBIO) last released its earnings results on Monday, March 16th. The company reported ($4.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.22) by ($3.32).

Insider Buying and Selling at Zenas BioPharma

In other news, Director Hongbo Lu bought 25,985 shares of Zenas BioPharma stock in a transaction that occurred on Wednesday, February 11th. The stock was purchased at an average cost of $22.50 per share, with a total value of $584,662.50. Following the completion of the transaction, the director directly owned 347,968 shares in the company, valued at $7,829,280. This trade represents a 8.07% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Patricia L. Allen purchased 15,700 shares of the stock in a transaction on Thursday, February 12th. The stock was acquired at an average cost of $24.85 per share, for a total transaction of $390,145.00. Following the acquisition, the director directly owned 15,700 shares in the company, valued at approximately $390,145. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders bought a total of 202,845 shares of company stock valued at $3,747,185 in the last quarter. Corporate insiders own 22.00% of the company’s stock.

Institutional Investors Weigh In On Zenas BioPharma

Institutional investors have recently added to or reduced their stakes in the stock. Invesco Ltd. lifted its position in shares of Zenas BioPharma by 28.9% during the 4th quarter. Invesco Ltd. now owns 187,968 shares of the company’s stock worth $6,825,000 after buying an additional 42,172 shares during the period. XTX Topco Ltd acquired a new stake in shares of Zenas BioPharma during the 4th quarter worth about $442,000. VARCOV Co. bought a new position in Zenas BioPharma during the 4th quarter valued at about $266,000. Voloridge Investment Management LLC bought a new stake in Zenas BioPharma during the fourth quarter worth about $4,845,000. Finally, Virtus Investment Advisers LLC bought a new stake in Zenas BioPharma during the fourth quarter worth about $238,000.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.